Clinical Trials
20
Active:17
Completed:2
Trial Phases
2 Phases
Phase 1:17
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Phase 1
17 (85.0%)Phase 2
3 (15.0%)Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- GeNeuro SA
- Target Recruit Count
- 203
- Registration Number
- NCT05497089
- Locations
- 🇮🇹
Clinica Metabolica dell'Università di Modena e Reggio Emilia, Modena, Italy
🇮🇹U.O.C. Malattie Infettive Tor Vergata, Policlincio Tor Vergata, Roma, Italy
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
Phase 2
Terminated
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: GNbAC1 Monoclonal Antibody
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GeNeuro SA
- Target Recruit Count
- 220
- Registration Number
- NCT03239860
- Locations
- 🇺🇦
Hospital, Kharkiv, Ukraine
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
Phase 2
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GeNeuro SA
- Target Recruit Count
- 270
- Registration Number
- NCT02782858
News
No news found